Chardan Capital Issues Pessimistic Outlook for PRQR Earnings

ProQR Therapeutics (NASDAQ:PRQR) – Investment analysts at Chardan Capital decreased their FY2024 earnings estimates for ProQR Therapeutics in a research note issued to investors on Sunday, November 10th. Chardan Capital analyst K. Nakae now expects that the biopharmaceutical company will post earnings per share of ($0.31) for the year, down from their prior estimate of ($0.28). The consensus estimate for ProQR Therapeutics’ current full-year earnings is ($0.34) per share. Chardan Capital also issued estimates for ProQR Therapeutics’ FY2025 earnings at ($0.34) EPS.

PRQR has been the subject of several other reports. Raymond James raised ProQR Therapeutics from an “outperform” rating to a “strong-buy” rating and upped their target price for the company from $6.00 to $14.00 in a report on Tuesday, October 29th. HC Wainwright upped their price objective on shares of ProQR Therapeutics from $5.00 to $10.00 and gave the company a “buy” rating in a research note on Friday, November 8th. One research analyst has rated the stock with a hold rating, three have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus target price of $7.13.

ProQR Therapeutics Stock Down 0.5 %

PRQR opened at $3.96 on Wednesday. The firm has a market cap of $323.45 million, a PE ratio of -12.38 and a beta of 0.26. The business has a fifty day simple moving average of $2.59 and a 200-day simple moving average of $2.13. ProQR Therapeutics has a fifty-two week low of $1.18 and a fifty-two week high of $4.62.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the business. BNP Paribas Financial Markets grew its stake in ProQR Therapeutics by 14.2% during the 3rd quarter. BNP Paribas Financial Markets now owns 58,801 shares of the biopharmaceutical company’s stock valued at $107,000 after acquiring an additional 7,300 shares in the last quarter. OneDigital Investment Advisors LLC boosted its holdings in shares of ProQR Therapeutics by 37.0% during the third quarter. OneDigital Investment Advisors LLC now owns 57,550 shares of the biopharmaceutical company’s stock worth $105,000 after purchasing an additional 15,550 shares during the period. Privium Fund Management B.V. grew its position in ProQR Therapeutics by 0.9% during the third quarter. Privium Fund Management B.V. now owns 5,632,388 shares of the biopharmaceutical company’s stock valued at $10,251,000 after purchasing an additional 51,663 shares in the last quarter. Ikarian Capital LLC increased its stake in ProQR Therapeutics by 2.3% in the 1st quarter. Ikarian Capital LLC now owns 483,583 shares of the biopharmaceutical company’s stock valued at $1,098,000 after buying an additional 10,958 shares during the period. Finally, EP Wealth Advisors LLC purchased a new stake in ProQR Therapeutics in the 1st quarter worth approximately $26,000. 32.65% of the stock is owned by institutional investors and hedge funds.

About ProQR Therapeutics

ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1).